Literature DB >> 21689086

Cardiac iron overload in transfusion-dependent patients with myelodysplastic syndromes.

Noémi B A Roy1, Saul Myerson, Anna H Schuh, Patricia Bignell, Roger Patel, Jim S Wainscoat, Simon McGowan, Emanuele Marchi, Wale Atoyebi, Tim Littlewood, Joseph Chacko, Paresh Vyas, Sally B Killick.   

Abstract

Transfusion-dependent myelodysplastic (MDS) patients are prone to iron overload. We evaluated 43 transfused MDS patients with T2* magnetic resonance imaging scans. 81% had liver and 16·8% cardiac iron overload. Liver R2* (1000/T2*), but not cardiac R2*, was correlated with number of units transfused (r=0·72, P<0·0001) and ferritin (r=0·53, P<0·0001). The area under the curve of a time-ferritin plot was found to be much greater in patients with cardiac iron loading (median 53·7x10(5) Megaunits vs. 12·2x10(5) Megaunits, P=0·002). HFE, HFE2, HAMP or SLC40A1 genotypes were not predictors of iron overload in these patients.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21689086     DOI: 10.1111/j.1365-2141.2011.08749.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  14 in total

1.  Comparison of myocardial and hepatic iron loading, assessed by MRI T2*, in patients with myelodysplastic syndromes, thalassaemia major and controls.

Authors:  Sophie Mavrogeni
Journal:  Blood Transfus       Date:  2011-12-21       Impact factor: 3.443

Review 2.  Iron overload in myelodysplastic syndromes (MDS).

Authors:  Norbert Gattermann
Journal:  Int J Hematol       Date:  2017-11-25       Impact factor: 2.490

3.  Serum ferritin levels at diagnosis predict prognosis in patients with low blast count myelodysplastic syndromes.

Authors:  Hiroshi Kawabata; Kensuke Usuki; Maki Shindo-Ueda; Junya Kanda; Kaoru Tohyama; Akira Matsuda; Kayano Araseki; Tomoko Hata; Takahiro Suzuki; Hidekazu Kayano; Kei Shimbo; Shigeru Chiba; Takayuki Ishikawa; Nobuyoshi Arima; Masaharu Nohgawa; Yasushi Miyazaki; Mineo Kurokawa; Shunya Arai; Kinuko Mitani; Akifumi Takaori-Kondo
Journal:  Int J Hematol       Date:  2019-07-29       Impact factor: 2.490

Review 4.  Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome.

Authors:  Niraj Shenoy; Nishanth Vallumsetla; Eliezer Rachmilewitz; Amit Verma; Yelena Ginzburg
Journal:  Blood       Date:  2014-06-12       Impact factor: 22.113

5.  Prospective cardiac magnetic resonance imaging survey in myelodysplastic syndrome patients: insights from an Italian network.

Authors:  Alessia Pepe; Michele Rizzo; Sara Galimberti; Claudia Baratè; Esther Natalie Oliva; Francesco Arcioni; Sergio Storti; Stefania Renne; Massimo Midiri; Gennaro Restaino; Vincenzo Positano; Maurizio Mangione; Antonella Meloni
Journal:  Ann Hematol       Date:  2021-03-19       Impact factor: 3.673

6.  Impact of HFE gene variants on iron overload, overall survival and leukemia-free survival in myelodysplastic syndromes.

Authors:  Mathias Schneeweiss-Gleixner; Georg Greiner; Susanne Herndlhofer; Julia Schellnegger; Maria-Theresa Krauth; Karoline V Gleixner; Friedrich Wimazal; Corinna Steinhauser; Michael Kundi; Renate Thalhammer; Ilse Schwarzinger; Gregor Hoermann; Harald Esterbauer; Manuela Födinger; Peter Valent; Wolfgang R Sperr
Journal:  Am J Cancer Res       Date:  2021-03-01       Impact factor: 6.166

7.  The role of magnetic resonance imaging in the evaluation of transfusional iron overload in myelodysplastic syndromes.

Authors:  Emmanouil Petrou; Sophie Mavrogeni; Vasiliki Karali; Genovefa Kolovou; Marie-Christine Kyrtsonis; Petros P Sfikakis; Panayiotis Panayiotidis
Journal:  Rev Bras Hematol Hemoter       Date:  2015-05-19

Review 8.  Management of the Older Patient with Myelodysplastic Syndrome.

Authors:  Rory M Shallis; Amer M Zeidan
Journal:  Drugs Aging       Date:  2021-08-03       Impact factor: 3.923

Review 9.  Targeting low-risk myelodysplastic syndrome with novel therapeutic strategies.

Authors:  Gaurang Trivedi; Daichi Inoue; Lingbo Zhang
Journal:  Trends Mol Med       Date:  2021-07-11       Impact factor: 15.272

10.  Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.

Authors:  Luca Malcovati; Eva Hellström-Lindberg; David Bowen; Lionel Adès; Jaroslav Cermak; Consuelo Del Cañizo; Matteo G Della Porta; Pierre Fenaux; Norbert Gattermann; Ulrich Germing; Joop H Jansen; Moshe Mittelman; Ghulam Mufti; Uwe Platzbecker; Guillermo F Sanz; Dominik Selleslag; Mette Skov-Holm; Reinhard Stauder; Argiris Symeonidis; Arjan A van de Loosdrecht; Theo de Witte; Mario Cazzola
Journal:  Blood       Date:  2013-08-26       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.